Skip to main content
Equibles
KYTX logo

KYTX · Kyverna Therapeutics, Inc. · Metrics

Track KYTX — free

Use KYTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.11 +0.28 (+4.80%)
Russell 2000 member Rebalance outlook locked
Market Cap
$360.55M
Shares
61.84M
Volume · Oct 20 398.94K Avg daily vol (3M) 843.88K

KYTX metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.83
Market cap
$360.55M

Price action

20 metrics
Price change (1W)
-6.1%
Price change (30D)
-18.1%
Price change (3M)
-19.5%
Price change (6M)
-48.2%
Price change (YTD)
-38.0%
Price change (1Y)
-12.1%
Trailing year
Price change (5Y)
—
52-week high
$11.25
52-week low
$5.67
Change from 52-week high
-48.2%
Change from 52-week low
+2.8%
Annualized volatility
89.5%
Annualized volatility (3M)
58.7%
Beta
2.3
RSI (14D)
35.5
Price vs SMA 50
-20.9%
Price vs SMA 200
-29.0%
Avg volume (3M)
843,874
Relative volume
1.0
Average dollar volume
$6.17M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
61.84M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.1
reciprocal yield 47.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-43.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-22

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$158.93M
Net income (TTM)
−$152.64M
Trailing 12 months
Diluted EPS (TTM)
$-2.93
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.06
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.94
Operating cash flow per diluted share (TTM)
$-3.06
Free cash flow per diluted share (TTM)
$-3.65
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$2.24
Stock compensation per diluted share (TTM)
$0.23
Book value per share
$3.85

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+40.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-92.2%
Return on assets
-69.4%
Debt / equity
0.2
Current ratio
9.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
9.1
Interest coverage
-88.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$174.54M
Latest balance sheet
Cash & equivalents
$31.81M
Total assets
$219.82M
Total debt
$24.88M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$158.75M
Capital expenditures (TTM)
$294,000
R&D (TTM)
$115.33M
SG&A (TTM)
—
Stock compensation (TTM)
$12.08M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
120
13F filer change QoQ
+8
Institutional ownership
61.3%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
1.0
Price vs estimated holder cost
-10.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.3%

Short interest

3 metrics
Short interest
15.6%
Latest settlement · 8.9 days to cover
Days to cover
8.9d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1994702 CUSIP 501976104 13F (30d) 6 filings 6 filers Visit website Investor relations